<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838967</url>
  </required_header>
  <id_info>
    <org_study_id>ID_IDCV_1301</org_study_id>
    <nct_id>NCT01838967</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of Cilnidipine and Valsartan</brief_title>
  <official_title>A Randomized, Open-label, Single Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Cilnidipine 10 mg and Valsartan 160 mg After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigate the potential pharmacokinetic drug-drug interaction between
      Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteers who receive Cilnidipine 10
      mg alone, Valsartan 160 mg , and both together in a 3 period repeatedly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, drug-tolerance, pharmacokinetics of Cilnidipine 10 mg or Valsartan
      160 mg monotherapy or Cilnidipine 10 mg and Valsartan 160 mg combination in healthy male
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Cilnidipine 10 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Valsartan 160 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Cilnidipine 10 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Valsartan 160 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of Cilnidipine 10 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Valsartan 160 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Cilnidipine 10 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Cilnidipine 10 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Valsartan 160 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Valsartan 160 mg</measure>
    <time_frame>1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>C - V - C+V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V - C - C+V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V - C+V - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C+V - V - C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C+V - C - V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - C+V - V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C - V - C+V</intervention_name>
    <description>Drug will be administered to according to C - V - C+V sequence for 3 period.</description>
    <arm_group_label>C - V - C+V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C - C+V - V</intervention_name>
    <description>Drug will be administered to according to C - C+V - V sequence for 3 period.</description>
    <arm_group_label>C - C+V - V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V - C - C+V</intervention_name>
    <description>Drug will be administered to according to V - C - C+V sequence for 3 period.</description>
    <arm_group_label>V - C - C+V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V - C+V - C</intervention_name>
    <description>Drug will be administered to according to V - C+V - C sequence for 3 period.</description>
    <arm_group_label>V - C+V - C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C+V - C - V</intervention_name>
    <description>Drug will be administered to according to C+V - C - V sequence for 3 period.</description>
    <arm_group_label>C+V - V - C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C+V - V - C</intervention_name>
    <description>Drug will be administered to according to C+V - V - C sequence for 3 period.</description>
    <arm_group_label>C+V - C - V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers, age 20 to 40 years

          2. The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 25 kg/m2
             and body weight are least 55 kg

          3. Subjects who have no congenital or chronic disease and no abnormal symptom or opinion

          4. Acceptable serum test, hematologic test, blood chemistry examination, urin test and
             ECG, physical examination during screening

          5. Subjects who have ability to comprehend the objectives, contents of study and property
             of study drug before participating in trial and have willingness to sign of informed
             consent in writing

        Exclusion Criteria:

          1. A subject with clinical evidence or history of hepatic (including carrier of hepatitis
             virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic,
             oncologic, psychiatric, or cardiovascular disease

          2. A subject with a history of gastrointestinal disease or surgery (except simple
             appendectomy or repair of hernia), which can influence the absorption of the study
             drug

          3. A subject with history of drug allergies (aspirin, antibiotics, including study drug
             etc.), or history of clinically significant allergies

          4. Systolic blood pressure &lt;100mmHg or Diastolic blood pressure &lt; 60 mmHg, systolic blood
             pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100mmHg(Sitting blood pressure)
             during the screening procedure.

          5. Presence or history of drug abuse or positive result in urine drug screening test

          6. Use any prescriptive medication, Korean traditional medication not considered
             acceptable by the clinical investigator during the last 14 days period before first
             dosing, or use any OTC medication not considered acceptable by the clinical
             investigator during the last 7 days period before first dosing (if used medication is
             considered acceptable by investigator, patients can be included)

          7. Participation in clinical trials of any drug within 60 days prior to the participation
             of the study

          8. Blood donation during 2 months or apheresis during 1 month before the study

          9. Use of alcohol over 21 units/weeks

         10. Smoker who smoke more than 20 cigarettes per day

         11. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products
             within 3 days prior to the participation of the study

         12. A subject who takes St John's wort or some food including the ingredient within 14
             days prior to the participation of the study

         13. Judged to be inappropriate for the study by the investigator after reviewing clinical
             laboratory results or other reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoung Sang You, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cilnidipin and valsartn</keyword>
  <keyword>pharmacokinetic drug drug interaction</keyword>
  <keyword>oral administration</keyword>
  <keyword>healthy male subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Cilnidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

